New drugs may make a dent in lung, ovarian cancer
For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy.
But the benefit in the study was so small — six extra weeks, on average — that it is raising fresh questions about the value of some costly new cancer medicines.
Eli Lilly and Co.’s drug Cyramza was tested in more than 1,200 patients. It is sold now for stomach cancer and costs $6,000 per infusion.
The study was discussed Saturday at a cancer conference in Chicago where doctors also reported progress with new drugs against relapsed ovarian cancer and chronic lymphocytic leukemia, the most common type of leukemia in adults.
WHYY is your source for fact-based, in-depth journalism and information. As a nonprofit organization, we rely on financial support from readers like you. Please give today.
The program funds habitat restoration and conservation initiatives throughout the Delaware River watershed.
7 hours ago
Artificial voices sound like us, but they lack fundamental qualities of human speech
Professor of linguistics Emily Bender discusses the limitations of speech powered by LLMs and why it’s fundamentally different from human speech.
1 day ago
Listen 21:03
How some endangered language speakers get creative with AI for preservation efforts
Revitalizing endangered Indigenous languages that have little or no digital presence is challenging with artificial intelligence—but not impossible.
1 day ago
Listen 11:05